Breast cancer is a hormone-dependent tumour, and estrogen is the main driver of the growth of this cancer cell. In addition to reducing estrogen production, trilostane can also regulate the binding of estrogen to different subtypes of estrogen receptors, and at the same time show the dual effects of α-estrogen receptor inhibitors and β-estrogen receptor agonists, and ultimately block and change the negative effects of estrogen on cancer cells.
Trilostane is used to treat Cushing's syndrome (hypercortisolism) and primary hyperaldosteronism, but is less effective than metyrapone for Cushing's syndrome (hypercortisolism). Trilostane also has a significant effect on lowering blood testosterone levels, which may be related to inhibition of its synthesis.
|Appearance||White to off-white powder||Conform|
|Residue on ignition||≤0.1%||0.02%|
|Loss on drying||≤0.5%||0.27%|
|Appearance:||White to off-white powder|
|Package details:||1kg/foil bag;25kg/drum|
Guaranteed the purity
High quality & competitive price
Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!